FDA committee to discuss CV risks of DPP-4s

FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on April 14 to discuss results from two CV outcomes trials of dipeptidyl peptidase-4 ( DPP-4) inhibitors marketed by AstraZeneca plc (LSE:AZN; NYSE:AZN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) to treat Type II diabetes. FDA will ask the committee to vote on recommended regulatory actions, such as additional study requirements, label

Read the full 609 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE